



# MULTAQ® (dronedarone): Focus on CV Outcomes in AF Treatment

National Satellite Broadcast

February 3, 2010

US.DRO.10.02.037

Please see accompanying full prescribing information, including boxed WARNING.

## **VOICE OVER SCRIPT:**

Welcome to this DVD-based program which highlights important information about the effective management of atrial fibrillation and important cardiovascular outcomes.

This program is adapted from a MULTAQ National Satellite Broadcast event that was attended live by over 2,300 healthcare providers in 96 locations. This unique educational program was sponsored by Sanofi-Aventis.

Let's go to the broadcast studio and join our host and expert panel .

## Welcome and Introductions

Panel appears on screen

Please see accompanying full prescribing information, including boxed WARNING.

### **MANUSH:**

Welcome to the MULTAQ National Satellite Broadcast event. Good evening, I'm Manush Samarodi, and you're joining four leading experts in the field of cardiology.

So let's meet them. Moderating is Dr. Eric Prystowsky. Dr. Prystowsky is a Consulting Professor at Duke University School of Medicine in Durham, North Carolina. He is also the Director at St. Vincent Hospital's Clinical Electrophysiology lab in Indianapolis, Indiana. Dr. Prystowsky will discuss the current treatment paradigm in atrial fibrillation. Joining Dr. Prystowsky is Dr. Augustus Grant. Dr. Grant is the Vice Dean for Faculty Enrichment at Duke University Medical School in Durham, North Carolina. He will explain atrial fibrillation pathophysiology and progression. Also presenting is Dr. Peter Kowey. Dr. Kowey is a Professor of Medicine and Clinical Pharmacology at Jefferson Medical College in Philadelphia, Pennsylvania. He is also Chief of Cardiovascular Diseases at Main Line Health System. He will present MULTAQ® (dronedarone), a clinical trial review. Also presenting is Dr. David Cannom. Dr. Cannom is the Director of Cardiology at Good Samaritan Hospital in Los Angeles, California, and Clinical Professor of Medicine at UCLA School of Medicine. He will present a patient case review, choosing the appropriate patient for MULTAQ.

...But now to start our program. Dr. Eric Prystowsky.

ERIC PRYSTOWSKY, MD, FACC: Thank you, Manush. And welcome, everybody, to this program.

## Objectives

- Describe the pathophysiology and progression of AF
- Review the current treatment paradigm and goals for AF
- Present outcomes data for MULTAQ
- Apply current clinical evidence to setting appropriate treatment goals and developing a treatment plan for patients with AF

Please see accompanying full prescribing information, including boxed WARNING.

### **DR. PRYSTOWSKY:**

The objectives for tonight's program are to describe the pathophysiology and progression of AFib, to review the current treatment paradigm and goals for AF, to present outcomes data for MULTAQ, and to apply current clinical evidence to setting appropriate treatment goals, and developing a treatment plan for patients with AF.